The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012

Monday, July 16, 2012

Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 201217:00 EDT Monday, July 16, 2012MONTREAL, July 16, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, August 2, 2012 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2012 second quarter.The dial-in number to participate on this call is (877) 876-8393, confirmation code 10552994.  International callers should dial (973) 200-3961, confirmation code 10552994. A replay will be available approximately two hours following the conclusion of the conference call to Thursday, August 8, 2012, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 10552994.The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at www.valeant.com.(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO) Contact Information:Laurie W. Little 949-461-6002 laurie.little@valeant.com SOURCE Valeant Pharmaceuticals International, Inc.